Production (Stage)
Corix Bioscience, Inc.
CXBS
$0.00
$0.000.00%
OTC PK
| 09/30/2017 | 06/30/2017 | 03/31/2017 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | -8.95% | 70.40% | 31.61% | ||
| Depreciation & Amortization | 425.00% | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | -8.42% | 70.40% | 31.61% | ||
| Operating Income | 8.42% | -70.40% | -31.61% | ||
| Income Before Tax | -58.30% | -261.10% | -166.62% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -58.30% | -261.10% | -166.62% | ||
| Earnings from Discontinued Operations | -114.78% | 55.77% | 61.93% | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -102.84% | -10.49% | 13.84% | ||
| EBIT | 8.42% | -70.40% | -31.61% | ||
| EBITDA | 8.77% | -- | -- | ||
| EPS Basic | 12.51% | 53.57% | 52.56% | ||
| Normalized Basic EPS | 29.00% | 26.37% | 25.76% | ||
| EPS Diluted | 12.51% | 53.57% | 52.56% | ||
| Normalized Diluted EPS | 29.00% | 26.37% | 25.76% | ||
| Average Basic Shares Outstanding | 131.94% | 137.87% | 81.74% | ||
| Average Diluted Shares Outstanding | 131.94% | 137.87% | 81.74% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||